VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Core Insights - VolitionRx Limited has made significant clinical and commercial progress, highlighting licensing momentum and advancements in various diagnostic technologies [1][2] Group 1: Licensing and Commercialization - The company is in active discussions with approximately 10 global diagnostic leaders for licensing agreements [1][2] - Anticipated announcements of additional agreements during 2026 as negotiations progress [2] Group 2: Clinical Developments - The Nu.Q® NETs assay is included in a $7.3 million government-backed DETECSEPS program in France for early sepsis detection [1] - A reimbursement submission for lung cancer testing in France is underway, with routine clinical use expected by Q4 2026 [1] - New clinical utility of the Nu.Q® NETs assay has been demonstrated for managing Hidradenitis Suppurativa, a disease affecting about 1% of the global population [1] Group 3: Market Opportunities - The Capture-Seq™ platform presents a $23 billion annualized opportunity in cancer detection [1][2] - The total addressable market for Nu.Q® NETs in sepsis and chronic conditions is estimated at $3.8 billion [2] - The Nu.Q® Vet (Canine/Feline) market is projected to exceed $1 billion, with the canine test already commercially available [2] Group 4: Veterinary Breakthroughs - The Nu.Q® Vet Feline assay achieved 100% specificity in detecting feline lymphoma, marking a significant advancement in veterinary diagnostics [1] - This breakthrough is expected to unlock a $5 million milestone payment upon publication in a peer-reviewed journal [1]